These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 17724976)
1. [Selective noradrenaline-dopamine reuptake inhibition (SNDRI). More latitude for antidepressive therapy]. MMW Fortschr Med; 2007 May; 149 Suppl 2():88-9. PubMed ID: 17724976 [No Abstract] [Full Text] [Related]
2. Wellbutrin versus generic bupropion. Med Lett Drugs Ther; 2008 Jul; 50(1290):54-5. PubMed ID: 18617874 [No Abstract] [Full Text] [Related]
3. [Successful treatment of depression in a Parkinson disease patient with bupropion]. Leentjens AF; Verhey FR; Vreeling FW Ned Tijdschr Geneeskd; 2000 Nov; 144(45):2157-9. PubMed ID: 11086491 [TBL] [Abstract][Full Text] [Related]
4. [Zyban in smoking cessation]. Flaten O Tidsskr Nor Laegeforen; 2001 Feb; 121(4):507-8. PubMed ID: 11255877 [No Abstract] [Full Text] [Related]
5. [Uneasiness about the safety of bupropion as an aid to smoking cessation unjustified]. Offerhaus L Ned Tijdschr Geneeskd; 2001 Oct; 145(42):2054. PubMed ID: 11695106 [No Abstract] [Full Text] [Related]
6. Bupropion and other non-nicotine pharmacotherapies. Roddy E BMJ; 2004 Feb; 328(7438):509-11. PubMed ID: 14988194 [No Abstract] [Full Text] [Related]
7. Psychopharmacology of smoking cessation in patients with mental illness. Selby P J Psychiatry Neurosci; 2006 Sep; 31(5):360. PubMed ID: 16951737 [No Abstract] [Full Text] [Related]
9. Augmentation of venlafaxine with bupropion: risks associated with a triple monoamine reuptake inhibition approach to partially responsive depression. Andrade C J Clin Psychiatry; 2013 Feb; 74(2):e119-21. PubMed ID: 23473356 [No Abstract] [Full Text] [Related]
10. Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments. Raskin S; Durst R Med Hypotheses; 2010 Dec; 75(6):544-6. PubMed ID: 20708340 [TBL] [Abstract][Full Text] [Related]
11. Bupropion, a possible antidepressant without negative effects on alcohol relapse. Ballesta A; Orio L; Arco R; Vargas A; Romero-Sanchiz P; Nogueira-Arjona R; de Heras RG; Antón M; Ramírez-López M; Serrano A; Pavón FJ; de Fonseca FR; Suárez J; Alen F Eur Neuropsychopharmacol; 2019 Jun; 29(6):756-765. PubMed ID: 31064683 [TBL] [Abstract][Full Text] [Related]
13. Agitated delirium associated with therapeutic doses of sustained-release bupropion. Mack DR; Barbarello-Andrews L; Liu MT Int J Clin Pharm; 2012 Feb; 34(1):9-12. PubMed ID: 22108791 [TBL] [Abstract][Full Text] [Related]
14. Bupropion: efficacy and safety in the treatment of depression. Saiz Ruiz J; Gibert J; Gutiérrez Fraile M; Bobes J; Vallejo J; Iglesias C; Iriarte V Actas Esp Psiquiatr; 2011; 39 Suppl 1():1-25. PubMed ID: 22983817 [No Abstract] [Full Text] [Related]
15. Once-daily bupropion associated with improved patient adherence compared with twice-daily bupropion in treatment of depression. McLaughlin T; Hogue SL; Stang PE Am J Ther; 2007; 14(2):221-5. PubMed ID: 17414593 [TBL] [Abstract][Full Text] [Related]
16. Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. Padwal R Curr Opin Investig Drugs; 2009 Oct; 10(10):1117-25. PubMed ID: 19777400 [TBL] [Abstract][Full Text] [Related]